Please ensure Javascript is enabled for purposes of website accessibility

3 Top Pharmaceutical Stocks to Buy Now

By Brian Feroldi - Updated Jul 18, 2018 at 10:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Great products, big dividends, and strong pipelines separate these three pharma giants from the crowd.

Worldwide pharmaceutical sales were roughly $1 trillion in 2016, according to Statista. That's a massive number that should grow over time as the global population continues to age.

Given the market size and natural tailwind, it shouldn't be surprising that many pharma companies have grown to become truly gigantic. For proof, here's a look at the market cap of 10 of the largest publicly traded pharmaceutical companies in the world:

Company Market Cap
Johnson & Johnson (JNJ -2.74%) $376 billion
Novartis AG  $235 billion
Pfizer $219 billion
AbbVie (ABBV -0.42%) $185 billion
Merck & Co.  $163 billion
Sanofi  $110 billion
Bristol-Myers Squibb (BMY -1.51%) $104 billion
GlaxoSmithKline $93 billion
Eli Lilly and Company $91 billion
AstraZeneca  $91 billion

Data source: Finviz.com.

So which of these big-pharma stocks should investors favor today? Here's why Johnson & Johnson, AbbVie, and Bristol-Myers Squibb are my three favorites.

Colorful drugs on top of hundred dollar bills

Image source: Getty Images.

Johnson & Johnson

While Johnson & Johnson might not be a "pure play" pharmaceutical stock -- slightly more than half of this company's revenue comes from medical device and consumer products sales -- there's no doubt that J&J's future will be powered by its pharmaceutical division. Last year J&J's pharma sales grew by 17%, which is far faster than the 8% and 3% growth rates posted by its medical device and consumer products segments, respectively.

What's behind the big jump in J&J's pharma sales? Investors can largely attribute the gains to the continued success of next-generation drugs. This includes the autoimmune-disease drug Stelara, the anticoagulant Xarelto, and the cancer drugs Imbruvica, Zytiga, and Darzalex. Growth in these top-selling medicines is more than offsetting the declines in J&J's top-selling drug Remicade, which is a legacy cancer drug facing increased competition from biosimilars.

J&J's plan to keep pharma sales heading in the right direction is straightforward. The company boasts a number of trials in place that promise to expand the labeling for many of the fast-growing drugs listed above. The recent acquisition of Actelion also added a few potential blockbusters to the company's lineup and should provide needle-moving revenue. Meanwhile, J&J's vast pipeline and broad list of partnerships promise to introduce new blockbuster drugs to its portfolio.

In total, J&J boasts a strong product lineup that is poised to grow rapidly over time. Combining this with the company's knack for making tuck-in acquisitions, improving margins, and buying back stock, Wall Street projects that overall profit growth will exceed 7% annually over the long term. That's not too shabby for an established industry giant that offers up a well-covered dividend yield of more than 2%.

Doctor and patient looking at a piece of paper and smiling

Image source: Getty Images.

AbbVie

AbbVie's long-term success is attributable to a single name: Humira. This anti-inflammatory drug has powered the company's top- and bottom-line growth for years and is currently ranked as the best-selling drug in the world. In 2017 Humira hauled in about $18 billion in total sales and accounted for more than 60% of AbbVie's revenue. As amazing as that number is, Humira is still poised to post substantial growth over the coming years.

There is a downside to having such a dominant drug, though: What happens to AbbVie when Humira finally loses patent protection?

AbbVie's management team has been pondering that question for years. Thankfully, CEO Rick Gonzalez recently shared his company's long-term growth plan with investors at the J.P. Morgan Healthcare Conference.

So what is the plan? First, the company will wheel and deal to ensure that Humira pumps out revenue for as long as possible. Next, AbbVie plans to emphasize growth in its other top-selling drugs -- namely the cancer drug Imbruvica and the hepatitis C drug Mavyret -- as much as possible. Finally, the company boasts a number of pipeline drugs that hold great promise. This includes an endometriosis drug called elagolix, both of which could turn into blockbusters.

Gonzalez predicted that, all told, AbbVie's non-Humira sales will eclipse $35 billion by 2025. For context, AbbVie's non-Humira sales in 2017 were about $13 billion. If achieved, that number should be big enough to offset the eventual Humira decline.

Beyond revenue growth, management also sees ample room for profit enhancement through margin expansion. The company's operating margin is "only" about 38% right now. Management believes it can ultimately bring that number up to 50% by 2020.

When added together, Wall Street believes that this one-two punch will drive 16% annualized profit growth over the next five years. That makes AbbVie one of the fastest-growing big-pharma companies in the world.

Turning to the dividend, AbbVie currently offers up a yield of 2.4% and boasts a long history of passing along increases to shareholders. With profits set to rise, I think investors can expect more of the same.

An assortment of colorful medications on top of $100 bills

Image source: Getty Images.

Bristol-Myers Squibb

Like many of its big-pharma brethren, Bristol-Myers Squibb recently muddled through a difficult period when it saw several top-selling drugs lose patent protection. Thankfully, the massive success of two recently launched megablockbuster drugs is more than offsetting those losses.

The first drug driving the turnaround is a blood thinner called Eliquis (which is being commercialized with the help of Pfizer). Eliquis is a best-of-breed anticoagulant that is wresting market share away from the legacy drug warfarin. It is also more than holding its own against J&J's next-generation drug Xarelto. Total Eliquis sales should come in around $5 billion for 2017, and still look to have plenty of room to run.

BMS's other wonder drug is Opdivo, an approved treatment for 11 different types of cancer. Opdivo is also flying off the shelves and, like Eliquis, should pull in nearly $5 billion in total sales in 2017. That's exciting, but management believes that Opdivo also holds promise to treat lung, renal-cell, gastric, and liver cancer. Each of these potential label-expansion claims could add another $1 billion to the drug's peak sales potential.

While Eliquis and Opdivo are clearly the stars of the show, BMS also owns a number of other fast-growing drugs that are driving financial gains. These include the rheumatoid arthritis drug Orencia and the cancer drugs Sprycel, Yervoy, and Empliciti. Combined, these drugs contribute another $5 billion or so to the company's top line, and are growing by double digits.

All told, market-watchers expect that these drugs will power earnings growth of more than 10% annually over the next five years. BMS's dividend yield of 2.5% looks like icing on the cake.

The Foolish bottom line

The aging of the baby-boomer generation should drive steady demand for prescription drugs in the years ahead. That's a great tailwind for drugmakers in general, but the three companies discussed above look particularly well-positioned to profit.

If you're a healthcare investor who likes to buy and hold great companies, I think all three of these big-pharma giants are excellent choices.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.13 (-2.74%) $-4.99
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$78.78 (-1.51%) $-1.21
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$152.49 (-0.42%) $0.65
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$92.03 (-2.53%) $-2.38
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$317.48 (-2.99%) $-9.79
Sanofi Stock Quote
Sanofi
SNY
$52.12 (-0.91%) $0.48
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$65.94 (-0.86%) $0.57
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.59 (-2.48%) $-1.28
Novartis AG Stock Quote
Novartis AG
NVS
$84.20 (-1.27%) $-1.08
GSK Stock Quote
GSK
GSK
$43.32 (-0.87%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.